Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE ACETATE versus HI COR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE ACETATE versus HI COR.
DEXAMETHASONE ACETATE vs HI-COR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin and leukotriene synthesis.
0.5-9 mg/day orally in divided doses every 6-12 hours; intravenously or intramuscularly as dexamethasone sodium phosphate; typical anti-inflammatory dose 0.75-9 mg/day. For cerebral edema: IV loading dose 10 mg, then 4 mg every 6 hours. For COVID-19: 6 mg IV or orally once daily for up to 10 days.
0.1-0.2 mg/kg intravenously once.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in adults; slightly prolonged in neonates (approximately 12-24 hours) and patients with hepatic impairment. Clinical context: Duration of HPA axis suppression may exceed the presence of measurable drug; single dose typically suppresses cortisol for 24-36 hours.
Terminal elimination half-life is 2-4 hours. Clinical context: Short half-life requires frequent dosing for sustained effect; accumulation possible in renal impairment.
Renal (primarily as glucuronide and sulfate conjugates) and biliary/fecal (minor). Approximately 65-80% of a dose is excreted in urine within 24 hours as 20-beta-dihydrodexamethasone (inactive) and conjugated metabolites; about 10-15% appears in feces. Less than 5% is excreted unchanged.
Renal excretion of unchanged drug and metabolites accounts for approximately 70-80% of elimination, with biliary/fecal excretion contributing 20-30%.
Category D/X
Category C
Corticosteroid
Corticosteroid